Sparta Systems and Veeva Systems announced plans to deliver a complete, fully integrated quality solution
Sparta Systems and Veeva Systems announced plans to deliver a complete, fully integrated quality solution. The two companies will integrate Sparta’s market-leading enterprise quality management solution, TrackWise, with Veeva Vault QualityDocs, a cloud-based document management solution to manage controlled documents across the enterprise. Bringing together quality process and document management in a single, end-to-end solution will enable life sciences companies to strengthen compliance, improve efficiency, and lower costs.
“Sparta’s strategic relationship with Veeva is a significant milestone as quality-conscious organizations move to streamline mission-critical work processes,” said Eileen Martinson, CEO of Sparta Systems. “Product safety incidents are growing as a result of supplier quality issues. The integration of these products, complemented by our soon-to-be-released cloud-based supplier quality solution, will help ensure safety and efficiency across the enterprise and supplier network.”
“Partnering with Sparta, the market leader in enterprise quality management systems, we have the opportunity to deliver greater strategic value for our joint customers,” said Peter Gassner, CEO of Veeva Systems. “Through the integration of TrackWise and Veeva’s cloud-based regulated content management solution, life sciences companies and their suppliers can now manage quality processes and quality documents together, eliminating the limitations and compliance risks of traditional, disconnected systems.”
The integration between TrackWise and QualityDocs is currently planned for release to customers in the first half of 2014.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.